Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Context Therapeutics Inc. (NASDAQ:CNTX) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.60.

Several analysts recently weighed in on CNTX shares. Guggenheim reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Tuesday. Piper Sandler boosted their target price on Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday. Wall Street Zen raised shares of Context Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Tuesday. Finally, JonesTrading initiated coverage on shares of Context Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 price target on the stock.

Context Therapeutics News Roundup

Here are the key news stories impacting Context Therapeutics this week:

• Positive Sentiment: Piper Sandler raised its price target, reflecting stronger upside expectations; this can boost investor sentiment and buying interest. Piper Sandler Raises Context Therapeutics Price Target
• Positive Sentiment: Guggenheim published a Buy rating on CNTX, another institutional endorsement that may support the rally. Guggenheim Buy Rating
• Positive Sentiment: D. Boral Capital issued a Buy rating, adding to the cluster of favorable analyst recommendations. D. Boral Capital Buy Rating
• Positive Sentiment: MSN reports a 13.33% increase in a published price target to $5.78, signaling bullish revision of fair value that can attract momentum traders. Price Target Increased to $5.78
• Negative Sentiment: Lifesci Capital cut multiple 2026 quarterly and full‑year EPS estimates (Q1–Q4 2026 and FY2026 now seen at about ($0.62) vs prior ~$($0.55)); the firm still carries a “Strong‑Buy” rating, but lowered earnings guidance increases short‑term downside risk if fundamentals or cash burn concerns persist.
• Negative Sentiment: HC Wainwright also trimmed Q1–Q4 2026 and multi‑year EPS forecasts (FY2026 lowered to ~$($0.60) from ~$($0.49) and later‑year estimates reduced), signaling analysts expect heavier near‑term losses than previously modeled — a negative for valuation and longer‑term profitability expectations.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $2.59 on Friday. The business has a fifty day moving average price of $2.48 and a two-hundred day moving average price of $1.63. The stock has a market capitalization of $237.97 million, a PE ratio of -6.82 and a beta of 1.96. Context Therapeutics has a fifty-two week low of $0.49 and a fifty-two week high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). As a group, sell-side analysts expect that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Trading of Context Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CNTX. State Street Corp increased its holdings in shares of Context Therapeutics by 8.5% during the fourth quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after buying an additional 13,000 shares in the last quarter. Blue Owl Capital Holdings LP lifted its stake in shares of Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after acquiring an additional 25,000 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Context Therapeutics during the 4th quarter valued at $43,000. Clear Harbor Asset Management LLC boosted its holdings in shares of Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Context Therapeutics during the 4th quarter worth $68,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.